During a press conference Tuesday at the International AIDS Conference in Vienna, Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases at NIH, describes the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial. The study is testing the safety and efficacy of microbicide gel containing the ARV drug tenofovir, and oral tablets containing tenofovir or a combination of tenofovir and emtricitabine known by the brand name Truvada.
The following is a guest post By Sharon Weir, Ph.D. of MEASURE Evaluation For almost 35 years, HIV/AIDS has been a household word across the globe. […]
TB High Level Meeting: Leaders call for commitments, cash and innovation to end global impacts of tuberculosis
NEW YORK – National leaders gathering here this week should not be thinking about whether they have the money needed to end the global public health […]
A trial to test the safety of, and immune response prompted by, the latest candidate for a vaccine to protect against Zika virus infection has begun […]